Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19

Last updated: March 15, 2021
Sponsor: South Valley University
Overall Status: Active - Recruiting

Phase

2/3

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04716569
SVU MED CIT0 23 4 21 1 120
  • Ages > 18
  • All Genders

Study Summary

Ivermectin showed a strong viricidal effect upon covid19 virus in vitro as proved by many authors according to many studies , covid virus stay in postnasal space for 4 days before starting general manifestation, so ivermectin mucoadhesive nanosuspension sprayed inside the nose and post nasal space may help in early management of covid19 and may play a great rule in prophylaxis as well

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • early covid19 pateints

Exclusion

Exclusion Criteria:

  • children and pregnant women

Study Design

Total Participants: 150
Study Start date:
January 20, 2021
Estimated Completion Date:
March 20, 2021

Study Description

150 patient with early covid is devided into two groups first group will receive regular protocol of drugs second group will receive ivermectin nasal spray in addition to regular protocl of drugs

Connect with a study center

  • Zaky Aref

    Qinā, Qina 83511
    Egypt

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.